Worldwide, 10 Million platelet concentrates are transfused every year. Platelets are small blood cells whose function is to stop bleeding.
Today, patients only rely on blood donations. These life-saving transfusions are facing recurrent shortage issues and present a risk of life-threatening complications for multi-transfused patients.
Inspired by the mechanisms of platelet generation in the bone marrow, HemostOD developed an innovative solution to produce ex vivo platelets. Our unique process allows generating high quantities of platelets in a short period of time.
HemostOD’s product provides the only efficient alternative to blood donor platelet transfusions. We create a new source of platelets, manufactured on demand, to relieve blood banks and hospitals. We provide reliable access to platelets for all.
Beyond transfusions, standardized manufacturable platelets also open the way to new treatment opportunities.
Inspired by platelet biology to save lives.
co – CSO Biology
co – CSO Engineering
HemostOD receives CHF 100'000 from the FIT Foundation. https://rb.gy/zk30ly
September 2nd, 2021 HemostOD raises CHF 1.7M in seed round financing: Press Release.
HemostOD wins Venture Kick's second stage of financial and entrepreneurial support. https://cutt.ly/EWlpgbU
HemostOD receives the support of Venture Kick's first stage. https://cutt.ly/8WlpmOQ
We do not have any open position at the moment, but we are always happy to hear about new talents. Please reach out to us by email at the address below.